CONMED Co. (NASDAQ:CNMD) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Monday. According to Zacks, “CONMED reported mixed first quarter 2016 results due to modest sales growth and higher operating expenses. However, the company raised its full-year 2016 guidance driven by lower foreign exchange […]
